Why Biodexa Pharmaceuticals (BDRX) Stock Is Up Today

Biodexa Pharmaceuticals (BDRX) is up 120.4% today. Here is some analysis on what might have caused this price movement. ([biodexapharma.com](https://biodexapharma.com/biodexa-announces-major-milestone-for-its-serenta-registrational-phase-3-trial-in-fap-2/))

Analysis: The most likely driver appears to be renewed speculative buying in a very small-cap biotech after Biodexa’s recent Phase 3 recruitment update for eRapa, even though there does not appear to be a fresh company announcement on September 11, 2026. This could also be because BDRX has a history of sharp moves tied to its tiny market value, reverse-split-adjusted share structure, and heavy retail trading interest. ([biodexapharma.com](https://biodexapharma.com/biodexa-announces-major-milestone-for-its-serenta-registrational-phase-3-trial-in-fap-2/))

Details:

Biodexa said on August 19, 2026 that 87 of 168 planned subjects had been recruited into its registrational Phase 3 Serenta trial, putting enrollment past the halfway mark. ([biodexapharma.com](https://biodexapharma.com/biodexa-announces-major-milestone-for-its-serenta-registrational-phase-3-trial-in-fap-2/))

The company said the study is running across 29 clinical sites in the U.S. and Europe, with additional Canadian sites expected, which may have kept attention on the program despite the lack of a same-day catalyst. ([biodexapharma.com](https://biodexapharma.com/biodexa-announces-major-milestone-for-its-serenta-registrational-phase-3-trial-in-fap-2/))

Nasdaq records show Biodexa completed a 10,000-for-1 reverse split of its ordinary shares and changed the ADS ratio to 1 ADS representing 50 ordinary shares on July 30, 2026, a setup that can amplify volatility. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1643918/000121465926009576/bio424b3_333278040.htm?utm_source=openai))

SEC filings from August also registered a large block of shares underlying warrants and pre-funded warrants for resale, underscoring that the stock has an active financing overhang even as traders chase momentum. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1643918/000121465926009509/j83261424b3.htm?utm_source=openai))

Sources:

Biodexa Pharmaceuticals, SEC, Nasdaq

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

EARLY ACCESS

Receive BDRX Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$BDRX Hedge Fund Activity

We have seen 1 institutional investors add shares of $BDRX stock to their portfolio, and 6 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

SABBY MANAGEMENT, LLC removed 51,494 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $149,847
HRT FINANCIAL LP removed 10,583 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $6,539
ARMISTICE CAPITAL, LLC removed 4,695 shares (-24.1%) from their portfolio in Q2 2026, for an estimated $13,662
GAMMA INVESTING LLC removed 1,553 shares (-56.3%) from their portfolio in Q2 2026, for an estimated $4,519
SBI SECURITIES CO., LTD. removed 122 shares (-80.8%) from their portfolio in Q2 2026, for an estimated $355
RHUMBLINE ADVISERS removed 16 shares (-84.2%) from their portfolio in Q2 2026, for an estimated $46
CAITONG INTERNATIONAL ASSET MANAGEMENT CO., LTD added 4 shares (+400.0%) to their portfolio in Q2 2026, for an estimated $11

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.